Research Analysts Set Expectations for MRKR FY2028 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at Brookline Capital Markets decreased their FY2028 earnings estimates for shares of Marker Therapeutics in a report issued on Saturday, August 15th. Brookline Capital Markets analyst L. Cann now expects that the company will earn $1.42 per share for the year, down from their previous estimate of $1.44. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.17) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ FY2029 earnings at $4.90 EPS and FY2030 earnings at $14.05 EPS.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.16. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 53.33%.

Other analysts have also recently issued research reports about the company. Weiss Ratings cut Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.00.

Marker Therapeutics Price Performance

NASDAQ MRKR opened at $1.16 on Tuesday. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $2.46. The company has a market capitalization of $19.34 million, a PE ratio of -2.83 and a beta of 1.50. The company has a fifty day moving average of $1.32 and a two-hundred day moving average of $1.42.

Institutional Trading of Marker Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in Marker Therapeutics by 41.8% during the 1st quarter. Renaissance Technologies LLC now owns 175,294 shares of the company’s stock worth $228,000 after purchasing an additional 51,644 shares during the period. NewEdge Advisors LLC acquired a new position in Marker Therapeutics in the fourth quarter valued at $222,000. Geode Capital Management LLC increased its stake in Marker Therapeutics by 35.3% in the fourth quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock valued at $194,000 after purchasing an additional 34,028 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after buying an additional 13,340 shares during the last quarter. Finally, LPL Financial LLC raised its holdings in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after buying an additional 24,500 shares during the last quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.